Announcement on the "Quality and Return Double Enhancement" Special Action Plan
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false records, misleading statements, or significant omissions.
Qianjiang Yong'an Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), in order to thoroughly implement the decision of the Central Financial Work Conference to "greatly improve the quality of listed companies" and the requirements of the new "Nine Articles" on promoting the improvement of listed companies' investment value, actively responds to the Shenzhen Stock Exchange's initiative to deeply carry out the "Quality and Return Double Enhancement" special action for Shenzhen-listed companies, and promote the company's high-quality development and improvement of investment value. Based on the company's long-term development strategy and actual operating conditions, the "Quality and Return Double Enhancement" special action plan is hereby formulated. This plan was reviewed and approved by the fourteenth meeting of the seventh Board of Directors on April 15, 2026, and the specific content is as follows:
I. Focus on Core Business and Improve Operational Quality
Since its establishment, the Company has always focused on the production, research and development, and sales of taurine. Relying on years of technical accumulation and deep market cultivation, it has gradually become a leading enterprise in the global taurine segment. Over the years, the Company has adhered to its core business, continuously optimized and expanded its industrial layout while consolidating its core competitiveness, and actively cultivated new profit growth points. At present, the Company's main business segments are taurine, health food, and special dietary food (creatine).